Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 1;5(2):451-458.
doi: 10.20517/cdr.2021.138. eCollection 2022.

Ovarian cancer recurrence: "is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?"

Tanja Pejovic  1   2 , Katherine Fitch  2 , Gordon Mills  1
Affiliations

Ovarian cancer recurrence: "is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?"

Tanja Pejovic et al. Cancer Drug Resist. .

Abstract

PolyADP ribose polymerase inhibitors (PARPi) have transformed the treatment of ovarian cancer. Particularly in high-grade serous ovarian cancer (HGSOC), a disease characterized by homologous recombination deficiency (HRD), PARPi have had a rapid and profound impact on the disease course, as well as biologic and biomarker definitions of HGSOC, thereby creating a paradigm shift in the approach to treatment. In this review, we discuss the role of PARPi in the maintenance treatment of HGSOC, its effect on platinum sensitivity, and cross-resistance between platinum and PARP inhibitors.

Keywords: PARP inhibitors; maintenance therapy; niraparib; olaparib; ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

All authors declared that there are no conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389–93. doi: 10.1200/JCO.1991.9.3.389. - DOI - PubMed
    1. Friedlander M, Trimble E, Tinker A, et al. Gynecologic Cancer InterGroup. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21:771–5. doi: 10.1097/IGC.0b013e31821bb8aa. - DOI - PubMed
    1. Hanker LC, Loibl S, Burchardi N, et al. AGO and GINECO study group. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23:2605–12. doi: 10.1093/annonc/mds203. - DOI - PubMed
    1. Lindemann K, Gao B, Mapagu C, et al. Australian Ovarian Cancer Study Group. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecol Oncol. 2018;150:239–46. doi: 10.1016/j.ygyno.2018.05.020. - DOI - PubMed
    1. Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012;107:588–91. doi: 10.1038/bjc.2012.307. - DOI - PMC - PubMed

LinkOut - more resources